跳到主要內容區塊
Google  

 

 

:::

[2012/07/27] Prof. Zee-Fen Chang's Group Revealed a Novel TMPK Inhibitor for Developing Mild Chemotherapies

[2012/07/27]

Prof. Zee-Fen Chang's Group Revealed a Novel TMPK Inhibitor for Developing Mild Chemotherapies

A research team led by Professor Zee-Fen Chang at Institute of Biochemistry and Molecular Biology has made an important discovery in cancer research and developed a new strategy in cancer treatment. The work was published in the July issue of Cancer cells. Professor Chang's press conference held in the Library Building 929 conference room on July 19, which attracted a lot of media attention.

The main problem of cancer chemotherapy is the lack of differentiation between tumor- and rapidly-dividing cells in normal tissues. Doxorubicin, a widely used anti-cancer drug causes DNA damage to kill highly proliferating cells which include tumor and normal proliferating cells. This causes a variety of unwanted side effects. Dr. Chang's group found that inhibition of thymidylate kinase (TMPK) can sensitize a variety of tumor cells to doxorubicin for killing. The team further uses a high-throughput luciferase assay to identify a cell-permeable inhibitor of hTMPK, YMU1. They found that YMU1 markedly increases doxorubicin sensitivity in many different tumor cells while having little effect on normal cycling cells. The mice therapy experiments also prove that YMU1 in conjunction with sub-lethal dose of doxorubicin greatly suppresses tumor growth. They proposed that YMU1 is a promising lead compound for the development of a very mild chemosensitization regimen.

The research paper was published in "Cancer Cell" on July 10, 2012.

 

 

Prof. Zee-Fen Chang and her group

Prof. Zee-Fen Chang (left 3) and her group


views